1.Clinical Observation of Bushenzhuanggutang Combined with Salmon Calcitonin see Calcimar in the Treatment of Renal Osteopathy
Xiaohui LI ; Yeming LU ; Yanping LIANG
Journal of Medical Research 2006;0(04):-
Objective To investigate the effect of Bushenzhuanggutang combined with salmon calcitonin see calcimar in the treatment of renal osteodystrophy,and explore the mechanism of treatment.Methods 48 patients with renal osteodystrophy were divided into two groups:combined treatment group and control group.The patients were treated with Bushenzhuanggutang and salmon calcitonin see calcimar in combined treatment group.The patients were treated with salmon calcitonin see calcimar in the other group.Then the levels of serum calcium、phosphorus,PTH and BUN、Scr were detected before and after the treatment.Results The level of serum calcium increased significantly in two groups,while the level of serum phosphorus and PTH decreased(P
2.The influence of valsartan on MAU of patients with diabetic nephropathy(DN) at early stage
Rongjun LIANG ; Yeming LU ; Xiaohui LI
Chinese Journal of Primary Medicine and Pharmacy 2011;18(12):1606-1607
Objective To explore influence of valsartan on MAU of patients with DN at early stage.Methods 163 patients with DN at early stage were randomly divided into experimental group and control group.Two groups were given routine therapy, and experimental group were added the therapy of valsartan.Period of treatment was 24 weeks, and compared the UAER, Cr, BUN of two groups.Results After treatment of 24 weeks, UAER, Cr, BUN of experimental groups was (142.4 ± 15.6) μg/min, ( 68.7 ±9.4) μmol/L, (3.5 ± 1.2 ) mmol/L, compared with (195.8±23.7)(μg/min,(93.8 ± 13.6) μmol/L, (6.3 ±1.5) mmol/L before treatment, had significant difference (t = 13.675,11.287,2.469,all P<0.05).Compared with( 199.6 ±24.7)μg/min,(87.7 ±11.3)μmol/L、(6.2 ± 1.3)mmol/L of control group after treatment, declined more significantly (t = 13.246,10.312,2.518,all P<0.05).There was no serious complications occurred in two groups.Conclusion Valsartan used in patients with DN at early stage,can significantly improve the function of kidney and enhance clinical effect,decline the side reaction.
3.The clinical study of resin absorptive devices combined with hemodialyzer in series treatment for patients with uremia
Yeming LU ; Xiaohui LI ; Jieyin SHAO
Journal of Chinese Physician 2001;0(02):-
Objective To study the effects of resin absorptive devices combined with hemodialyzer in series treatment for patients with uremia.Methods Sixty maintenance hemodialysis patients with uremia were randomly divided into two groups: the experimental group and control group. The patients in experimental group were given the treatment for traditional hemodialysis two or three times a week,combined with the treatment for resin absorption twice a month.The patients in the control group were only given the treatment for traditional hemodialysis two or three times a week.The middle molecular substance(MMS),beta(2) microglobulin(?_2-MG),blood urea nitrogen,creatinine,albumin,globulin,the counts of red blood,hemoglobin,the change of blood pressure and clinical manifestation of the patients were observed before and three months after the treatment respectively.Results The rates of clearance of MMS and ?_2-MG were significantly higher in the experimental group than those of the control group(P
4.Biological mechanism and value of PIVKA-Ⅱ in the diagnosis and prognosis of hepatocellular carcinoma
Zheping MA ; Yuying SHAN ; Yeming ZHOU ; Caide LU
Chinese Journal of Hepatobiliary Surgery 2021;27(4):309-313
Hepatocellular carcinoma is a common malignancy of digestive system. Tumor markers are important for the early diagnosis and prognosis of hepatocellular carcinoma. Protein induced by vitamin K absence or antagonist-Ⅱ (PIVKA-Ⅱ) is of high specificity and sensitivity in hepatocellular carcinoma diagnosis. In addition, previous studies suggested that PIVKA-Ⅱ played a role in proliferation, invasion and metastasis of hepatocellular carcinoma and could be used for prognosis of hepatocellular carcinoma. This article reviewed the recent advances in the underlying biological mechanism of PIVKA-Ⅱ in hepatocellular carcinoma and concluded the value of PIVKA-Ⅱ in hepatocellular carcinoma diagnosis and prognosis.
5.Molecular subtyping of cholangiocarcinoma and its potential clinical application
Jingshu TONG ; Yeming ZHOU ; Caide LU ; Changjiang LU ; Jing HUANG
Chinese Journal of Hepatobiliary Surgery 2021;27(12):954-957
Intrahepatic cholangiocarcinoma (ICC) has a high degree malignancy, and its incidence has gradually increased in recent years. Surgery is still the only curative treatment for ICC to achieve long-term survival, but its onset is hidden, and most patients have lost the opportunity of operation when they are diagnosed. ICC shows significant heterogeneity. With the development of the second generation sequencing technology, the tumor patterns of ICC, such as DNA, RNA, epigenetic, protein, microenvironment and so on, have been gradually discovered. The purpose of this article is to review the research progress of molecular typing and clinical application of ICC in recent years.
6.Impact of morphological classification of intrahepatic cholangiocarcinoma on long-term prognosis
Yeming ZHOU ; Yangke HU ; Wei JIANG ; Jihan SUN ; Yin JIANG ; Yongfei HUA ; Jing HUANG ; Chunnian WANG ; Caide LU
Chinese Journal of Hepatobiliary Surgery 2020;26(10):762-766
Objective:To study the relationship between morphologic classification and prognosis of patients with intrahepatic cholangiocarcinoma (ICC).Methods:The clinicopathologic data of 125 ICC patients who underwent R 0 resection at the Ningbo Medical Center Li Huili Hospital from January 2011 to May 2019 were retrospectively analyzed. This cohort consisted of 67 males and 58 females, aged 26.0 to 82.0 (63.5±9.5) years old. Based on the resected specimens, the patients were divided into the mass forming type, periductal infiltrating type and mixed type. The survival rates and recurrence-free survival outcomes of the patients among the three types were compared, and the risk factors that influenced prognosis were analyzed. Results:Using the predetermined inclusion and exclusion criteria, 16 patients with missing data and other causes of death were excluded from the initial 125 patients. Also, as the number of the mixed type was small, these patients were excluded. Finally 62 patients in the mass forming type and 42 patients in the periductal infiltrating type were analyzed. In the mass forming group, there were 32 males and 30 females, aged (63.1±9.1) years. In the perivascular infiltration group, there were 22 males and 20 females, aged (64.1±10.2) years. The 1-, 3-, 5-year survival rates of the mass forming group were 78.1%, 33.2%, 18.9% (median survival 25 months). The 1-, 3-, 5-year survival rates of the periductal infiltrating type were 63.3%, 8.3%, 6.1% (median survival 15 months). There were statistically significant differences between the two groups ( P<0.05). The median recurrence-free survival for the mass forming and the periductal infiltrating groups were 18 and 11 months, respectively, with a statistically significant differences between them ( P<0.05). Univariate and multivariate analysis showed that TNM staging Ⅲ~Ⅳ ( HR=2.966, 95% CI: 1.549-5.679) and periductal infiltrating type ( HR=2.403, 95% CI: 1.236-4.670) were independent risk factors for survival of these patients after operations. TNM staging Ⅲ~Ⅳ ( HR=2.466, 95% CI: 1.325-4.589), low grade differentiation ( HR=0.528, 95% CI: 0.299-0.934) and periductal infiltrating type ( HR=2.432, 95% CI: 1.295-4.565) were independent risk factors for relapse-free survival of these patients ( P<0.05). Conclusions:Morphological classification was found to be an independent risk factor for prognosis of ICC patients in this study, with significantly worse long-term prognosis when compared with the mass forming type.
7. Progress of targeted therapy of intrahepatic cholangiocarcinoma
Yeming ZHOU ; Wei JIANG ; Jing HUANG ; Yongfei HUA ; Caide LU
Chinese Journal of Hepatobiliary Surgery 2019;25(12):956-960
The incidence of intrahepatic cholangiocarcinoma (ICC) has been increasing year by year. For most patients, surgical resection is not suitable when they are diagnosed as ICC. Conventional chemotherapy and radiotherapy are not effective for the long-term survival rate of ICC patients and lead to the poor overall prognosis. In recent years, with the deepening understanding about the molecular mechanism of biliary malignant tumors, some key genes and signaling pathways related to the pathogenesis of ICC have been identified, providing new ideas for the targeted therapy. In this paper, major molecular mechanisms and targeted therapies of ICC are reviewed.